VK-2809

VK-2809 is an experimental drug that is currently being studied for its potential use in the treatment of non-alcoholic steatohepatitis (NASH) and hypercholesterolemia. It is a small molecule, orally administered thyroid receptor beta (TRβ) agonist that is being developed by Viking Therapeutics.

Mechanism of Action

VK-2809 works by selectively activating the thyroid hormone receptor beta (TRβ), which is primarily found in the liver and kidneys. This selective activation is believed to lead to the reduction of liver fat content, inflammation, and fibrosis in patients suffering from NASH. In addition, it is also thought to lower plasma low-density lipoprotein cholesterol (LDL-C), a major risk factor for cardiovascular diseases.

Clinical Trials

VK-2809 has undergone Phase 2 clinical trials for the treatment of NASH and hypercholesterolemia. The results from these trials have shown a significant reduction in liver fat content and LDL-C levels in patients treated with VK-2809.

Potential Side Effects

As with any drug, VK-2809 has the potential to cause side effects. However, the specific side effects of VK-2809 are currently unknown as the drug is still in the experimental stages.

Future Developments

Further studies are needed to fully understand the potential benefits and risks of VK-2809. If successful, VK-2809 could provide a new treatment option for patients suffering from NASH and hypercholesterolemia.

VK-2809 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia